Healthy VolunteersNCT01322243
Effect of Metabolic State on Anxiety in Human Subjects
A study testing Dietary manipulation in people with Healthy Volunteers, run by Rockefeller University at 1 site in United States.
Trial summary
In this study, we would like to explore the hypothesis that changes in metabolic state, induced by altering hormone levels and patterns of neural activity, affect the experience of anxiety in humans. We will also investigate if there is a link between high anxiety and higher caloric intake. Read more about this study
- Who is it for?
- Ages 20 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers
- What is being tested?
- Dietary manipulation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2011to Feb 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Men and women aged 20 - 40 years.
- Body Mass Index (BMI) from 19.0 to 25.0 for the lean population or Body Mass Index (BMI) equal to or greater than 30 for the obese population and under 300lbs (136.07kg.)
- Fluent in English
- Females must report a normal menstrual cycle length defined as from 24-35 days, with a period lasting from 2-7 days
- Stable weight (+/- 5 %) for at least three months prior to each admission and under 300 lbs (136.07kg.)
Who cannot join
- Weight of > 300 lbs (136.07kg.)
- Patients may not have had > 550 mL of blood drawn within 8 weeks of study entry.
- Less than 8 weeks after receiving an investigational new drug (IND). Patients must have a minimum of an 8 week washout period.
- Left-handedness.
- Any employee of Rockefeller University who knows the details of this study
- Reported history of claustrophobia.
Show all 25Show fewer
- Reported history of metal implants, pacemaker, IUD, braces, or tattoos less then 6 months old.
- Reported history of smoking, chewing tobacco or use of nicotine patches within the previous 3 months.
- Reported history of alcohol abuse/dependence.
- Reported use of prescription medication for pain, anxiety or sleep more than once a week.
- Reported daily ingestion of herbal (including melatonin) or dietary supplements within one month prior to the screening.
- Reported use of medications or herbal supplements that affect appetite or body weight within the previous three months.
- Reported history of using the following medications: glucocorticoids, anti-seizure medications, thyroid hormones in the past six months.
- Reported Psychiatric disorder requiring medication or treatment.
- Reported history of cardiac disease.
- Reported history of illnesses that affect metabolic hormone levels: renal or hepatic failure, type 1 or type 2 diabetes, lymphoma, hypogonadism, malabsorption/malnourishment, hypo- or hyper-thyroidism, hypercortisolism or any endocrinopathies.
- Reported history of physical exercise >2 hours per day.
- Reported history by female subjects of amenorrhea (no periods for longer than 3 months (even with negative uhCG) and oligomenorrhea (length greater than 35 days.)
- Pregnant (verified by urine hCG) or breast-feeding within the past 3 months.
- Eating disorder as suggested by at least 2 'yes' answers on the SCOFF Eating Disorder Questionnaire.
- Alcohol dependence as suggested by at least 2 'yes' answers on the CAGE Questionnaire.
- Current use of any illicit drug (including "recreational use") as verified by urine toxicology test.
- Anemia defined as Hgb < 12g/dL for male subjects < 11g/d/L for female subjects.
- TSH level that is outside the reference range of 0.3 - 0.5 mU/L or free T4 level that is outside the reference range of 4.5 - 11.2 mcg/dL (performed only if an abnormal thyroid gland identified on physical examination.)
- History, physical, social or lab findings suggestive of any medical or psychological condition that would, in the opinion of the PI, make the candidate ineligible for the study.
Trial locations and contacts
1 site in 1 country.
United States1 site
The Rockefeller University
New York, New York, 10065
About this study
In this study, we would like to explore the hypothesis that changes in metabolic state, induced by altering hormone levels and patterns of neural activity, affect the experience of anxiety in humans. We will also investigate if there is a link between high anxiety and higher caloric intake. Our aim is to characterize whether changes in current metabolic state systematically influence anxiety induced by a well established behavioral task known as the threat of shock. The neural regions activated by this behavioral task in healthy subjects have been well characterized. We have a priori regions of interest that include the insula, anterior cingulate cortex, hypothalamus, amygdala, and prefrontal cortex. As our primary outcome, we will assess neural activation with whole-brain functional magnetic resonance imaging to determine whether brain regions are differentially engaged when subjects experience anxiety across different metabolic states. We will correlate these changes with psychophysiological measures of anxiety and metabolic state.
Read the detailed description
There is evidence that our subjective experience of the world is strongly influenced by our metabolic state, the status of our body's energy reserves and level of hunger. Hormones that regulate appetite, food ingestion and body weight apparently also exert their action on neuroanatomical circuits involved in the generation of psychological states. Previous research indicates that an individual's metabolic state may influence their susceptibility to and experience of anxiety. Conversely, stress can also modulate appetite and body weight regulation. There are many clinical implications of the bidirectional relationship between stress/anxiety and metabolic state/energy regulation but two of the most important ones are obesity and eating disorders. In terms of obesity, the high recidivism after successful weight loss underscores the limited use of caloric restriction to treat obesity. It is unknown whether dieting (fasting) increases anxiety, which eventually may undermine an individual's motivation to restrict food intake. Research shows that anxiety can increase appetite and exacerbate the physical and psychological manifestations associated with hunger. However, there is a paucity of experimental data establishing whether the metabolic changes associated with fasting influence the experience of stress and possibly, an individual's ability to continue dieting for an extended period of time. In the setting of both obesity and anorexia nervosa, the levels of metabolic hormones are different to those found in people of normal body weight. It is therefore likely that the activation of brain regions associated with energy and body weight regulation is abnormal. Many of these brain regions are also involved in the control of anxiety responses. The fact that there is a high comorbidity between anorexia nervosa and anxiety disorders indicates the potential contribution of metabolic states to the perception of stress.
To better understand the relationship between metabolic state and anxiety, we will examine whether changes in metabolic state influence anxiety in human subjects. We will use whole-brain functional magnetic resonance imaging (fMRI) to identify the neural mechanisms that underlie metabolic state-dependent changes in the response to anxiety-inducing stress. In a randomized crossover design, participants will be tested in a well-established behavioral task that elicits anticipatory anxiety in two separate sessions that differ with respect to their metabolic states. We aim to perform a fine-grain analysis of changes in neural and physiological responses to this anxiety-inducing task as a function of metabolic state. Using fMRI as well as non-invasive psychophysiological measures, we will characterize whether there are systematic differences in the neural and psychophysiological experience of anxiety across different metabolic states in obese as compared to lean individuals.
- Conditions
- Healthy Volunteers
- Being tested
- Dietary manipulation
- Keywords
- Anxiety, Metabolic state, Stress
- Medical subject headings
- Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietary manipulationOther
Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
| Study group | Role | What they receive |
|---|---|---|
| Dietary Intervention: Fasted State | Other | Participants will be randomized to a dietary intervention of a fasted or fed group upon admission. Receives: Other: Dietary manipulation |
| Dietary Intervention: Fed State | Other | Participants will be randomized to a dietary intervention of a fasted or fed group upon admission Receives: Other: Dietary manipulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Functional magnetic resonance imaging (fMRI) blood oxygenation level dependent (BOLD) signals as indications of neural activity during exposure to an anxiety-inducing stress.
Measured: 4 years
Secondary outcomes (2)
Physiological and behavioral parameters of emotional and metabolic state.
Physiologic and behavioral assessment:
Metabolic state:
- Hormone levels will be obtained every morning during the two days of fasting or normal food consumption
- Subjective measures of metabolic state will be accomplished through the use of the hunger questionnaire and the hunger visual analog scale.
- Body composition will be obtained on the first and last days of admission.
- Food consumption measured in calories immediately after the fMRI experiment.
Anxiety state:
- Salivary cortisol tests will be performed
- Physiological measures of anxiety, in addition to plasma ACTH, salivary cortisol testing, plasma epinephrine and norepinephrine
- Emotional status will be evaluated through the use of the questionnaires
Measured: 4 years
Response inhibition (impulse control) is also a secondary outcome for this study
Impulse control will be assessed with the validated cognitive task
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2011 (estimated)
- Study startMar 2011
- Primary completionFeb 2013
- Study completionFeb 2013
Why it stopped: Due to mechanical issue with device
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy VolunteersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rockefeller University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ana Emiliano, MD, Principal investigator, The Rockefeller University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01322243
- Sponsor's protocol ID
- EKE-0724
- Status last verified
- May 2013
- First submitted
- 22 Mar 2011
- Last updated
- 20 May 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Metabolic State on Anxiety in Human Subjects
- ClinicalTrials.gov ID
- NCT01322243
- Acronym / sponsor ID
- EKE-0724
- Conditions
- Healthy Volunteers
- Keywords
- Anxiety, Metabolic state, Stress
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Due to mechanical issue with device
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Rockefeller UniversityUniversity, hospital or other
- Study start
- Mar 2011
- Primary completion
- Feb 2013 (actual)
- Study completion
- Feb 2013 (actual)
- First posted
- 24 Mar 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study, we would like to explore the hypothesis that changes in metabolic state, induced by altering hormone levels and patterns of neural activity, affect the experience of anxiety in humans. We will also investigate if there is a link between high anxiety and higher caloric intake. Our aim is to characterize whether changes in current metabolic state systematically influence anxiety induced by a well established behavioral task known as the threat of shock. The neural regions activated by this behavioral task in healthy subjects have been well characterized. We have a priori regions of interest that include the insula, anterior cingulate cortex, hypothalamus, amygdala, and prefrontal cortex. As our primary outcome, we will assess neural activation with whole-brain functional magnetic resonance imaging to determine whether brain regions are differentially engaged when subjects experience anxiety across different metabolic states. We will correlate these changes with psychophysiological measures of anxiety and metabolic state.
Detailed description
There is evidence that our subjective experience of the world is strongly influenced by our metabolic state, the status of our body's energy reserves and level of hunger. Hormones that regulate appetite, food ingestion and body weight apparently also exert their action on neuroanatomical circuits involved in the generation of psychological states. Previous research indicates that an individual's metabolic state may influence their susceptibility to and experience of anxiety. Conversely, stress can also modulate appetite and body weight regulation. There are many clinical implications of the bidirectional relationship between stress/anxiety and metabolic state/energy regulation but two of the most important ones are obesity and eating disorders. In terms of obesity, the high recidivism after successful weight loss underscores the limited use of caloric restriction to treat obesity. It is unknown whether dieting (fasting) increases anxiety, which eventually may undermine an individual's motivation to restrict food intake. Research shows that anxiety can increase appetite and exacerbate the physical and psychological manifestations associated with hunger. However, there is a paucity of experimental data establishing whether the metabolic changes associated with fasting influence the experience of stress and possibly, an individual's ability to continue dieting for an extended period of time. In the setting of both obesity and anorexia nervosa, the levels of metabolic hormones are different to those found in people of normal body weight. It is therefore likely that the activation of brain regions associated with energy and body weight regulation is abnormal. Many of these brain regions are also involved in the control of anxiety responses. The fact that there is a high comorbidity between anorexia nervosa and anxiety disorders indicates the potential contribution of metabolic states to the perception of stress.
To better understand the relationship between metabolic state and anxiety, we will examine whether changes in metabolic state influence anxiety in human subjects. We will use whole-brain functional magnetic resonance imaging (fMRI) to identify the neural mechanisms that underlie metabolic state-dependent changes in the response to anxiety-inducing stress. In a randomized crossover design, participants will be tested in a well-established behavioral task that elicits anticipatory anxiety in two separate sessions that differ with respect to their metabolic states. We aim to perform a fine-grain analysis of changes in neural and physiological responses to this anxiety-inducing task as a function of metabolic state. Using fMRI as well as non-invasive psychophysiological measures, we will characterize whether there are systematic differences in the neural and psychophysiological experience of anxiety across different metabolic states in obese as compared to lean individuals.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dietary Intervention: Fasted State | Other | Other: Dietary manipulationParticipants will be randomized to a dietary intervention of a fasted or fed group upon admission. |
| Dietary Intervention: Fed State | Other | Other: Dietary manipulationParticipants will be randomized to a dietary intervention of a fasted or fed group upon admission |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Men and women aged 20 - 40 years.
- Body Mass Index (BMI) from 19.0 to 25.0 for the lean population or Body Mass Index (BMI) equal to or greater than 30 for the obese population and under 300lbs (136.07kg.)
- Fluent in English
- Females must report a normal menstrual cycle length defined as from 24-35 days, with a period lasting from 2-7 days
- Stable weight (+/- 5 %) for at least three months prior to each admission and under 300 lbs (136.07kg.)
Key exclusion criteria (25 listed)
- Weight of > 300 lbs (136.07kg.)
- Patients may not have had > 550 mL of blood drawn within 8 weeks of study entry.
- Less than 8 weeks after receiving an investigational new drug (IND). Patients must have a minimum of an 8 week washout period.
- Left-handedness.
- Any employee of Rockefeller University who knows the details of this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietary manipulationParticipants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days. | Other | Dietary Intervention: Fasted State, Dietary Intervention: Fed State |
Primary outcome
Functional magnetic resonance imaging (fMRI) blood oxygenation level dependent (BOLD) signals as indications of neural activity during exposure to an anxiety-inducing stress.
Time frame: 4 years
2 secondary outcomes
Physiological and behavioral parameters of emotional and metabolic state.
Time frame: 4 years
Response inhibition (impulse control) is also a secondary outcome for this study
Time frame: 4 years
Results and safety
The study was stopped early (reason given: Due to mechanical issue with device). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2013.
Related trials for Healthy Volunteers
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Not yet recruitingObservational study
Screening Protocol
Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ana Emiliano, MD principal investigator
The Rockefeller University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dietary manipulation in people with Healthy Volunteers, run by Rockefeller University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 20 May 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Due to mechanical issue with device). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Functional magnetic resonance imaging (fMRI) blood oxygenation level dependent (BOLD) signals as indications of neural activity during exposure to an anxiety-inducing stress. (time frame: 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2013.